A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Exclusion Criteria

• •1. Male subjects who are not willing to use a local contraception (such as condom) from the time of study entry and for three months following the last study drug application.
• •2. Female subjects who are pregnant, of child-bearing potential or who are breast feeding.
• •3. Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months(adalimumab, alefacept, infliximab), 4 months(ustekinumab) or 4 weeks/5 half-lives (which-ever islonger) for experimental biological products prior to randomisation and during the study.
• •4. Systemic treatments with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (e.g., corticosteroids, retinoids, immune suppressants) within the 4-week period prior to randomisation and during the study.
• •5. Subjects using one of the following topical drugs for the treatment of psoriasis within the 4 week period prior to randomisation and during the study:
• •\- Potent or very potent (WHO group III-IV) corticosteroids.
• •6. Subjects using of phototherapy within the following time periods prior to randomisation and during the study:
• •* PUVA (4 weeks)
• •* UVB (2 weeks)
• •7. Subjects using one of the following topical drugs for the treatment of psoriasis within two weeks prior to randomisation and during the study:
• •* WHO group I-II corticosteroids (except if used for treatment of scalp and/or facial psoriasis)
• •* Topical retinoids
• •* Vitamin D analogues
• •* Topical immunomodulators (e.g. macrolides)
• •* Anthracen derivatives
• •* Tar,
• •* Salicylic acid.
• •8. Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis
• •9. Subjects with known/suspected disorders of calcium metabolism associated with hypercalcemia within the last 10 years, based on medical history and/or subject interview
• •10. Subjects who have received treatment with any non-marketed drug substance (i.e., an agent which has not yet been made available for clinical use following registration) within the 4 week period prior to randomisation or longer, if the class of the substance requires a longer washout as defined above (e.g., biological treatments)
• •11. Subjects with current participation in any other interventional clinical, based on interview of the subject